216 related articles for article (PubMed ID: 23219284)
1. Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial.
Weber MA; Jamerson K; Bakris GL; Weir MR; Zappe D; Zhang Y; Dahlof B; Velazquez EJ; Pitt B
Lancet; 2013 Feb; 381(9866):537-45. PubMed ID: 23219284
[TBL] [Abstract][Full Text] [Related]
2. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial.
Bakris GL; Sarafidis PA; Weir MR; Dahlöf B; Pitt B; Jamerson K; Velazquez EJ; Staikos-Byrne L; Kelly RY; Shi V; Chiang YT; Weber MA;
Lancet; 2010 Apr; 375(9721):1173-81. PubMed ID: 20170948
[TBL] [Abstract][Full Text] [Related]
3. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients.
Jamerson K; Weber MA; Bakris GL; Dahlöf B; Pitt B; Shi V; Hester A; Gupte J; Gatlin M; Velazquez EJ;
N Engl J Med; 2008 Dec; 359(23):2417-28. PubMed ID: 19052124
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the efficacy and safety profiles of two fixed-dose combinations of antihypertensive agents, amlodipine/benazepril versus valsartan/hydrochlorothiazide, in patients with type 2 diabetes mellitus and hypertension: a 16-week, multicenter, randomized, double-blind, noninferiority study.
Lee IT; Hung YJ; Chen JF; Wang CY; Lee WJ; Sheu WH
Clin Ther; 2012 Aug; 34(8):1735-50. PubMed ID: 22784975
[TBL] [Abstract][Full Text] [Related]
5. Baseline characteristics in the Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: a hypertensive population at high cardiovascular risk.
Weber MA; Bakris GL; Dahlöf B; Pitt B; Velazquez E; Gupte J; Lefkowitz M; Hester A; Shi V; Weir M; Kjeldsen S; Massie B; Nesbitt S; Ofili E; Jamerson K
Blood Press; 2007; 16(1):13-9. PubMed ID: 17453747
[TBL] [Abstract][Full Text] [Related]
6. Amlodipine+benazepril is superior to hydrochlorothiazide+benazepril irrespective of baseline pulse pressure: subanalysis of the ACCOMPLISH trial.
Skoglund PH; Svensson P; Asp J; Dahlöf B; Kjeldsen SE; Jamerson KA; Weber MA; Jia Y; Zappe DH; Östergren J;
J Clin Hypertens (Greenwich); 2015 Feb; 17(2):141-6. PubMed ID: 25529596
[TBL] [Abstract][Full Text] [Related]
7. Comparison of benazepril plus amlodipine or hydrochlorothiazide in high-risk patients with hypertension and coronary artery disease.
Bakris G; Briasoulis A; Dahlof B; Jamerson K; Weber MA; Kelly RY; Hester A; Hua T; Zappe D; Pitt B;
Am J Cardiol; 2013 Jul; 112(2):255-9. PubMed ID: 23582626
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
Ruilope LM; Malacco E; Khder Y; Kandra A; Bönner G; Heintz D
Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306
[TBL] [Abstract][Full Text] [Related]
9. The diabetes subgroup baseline characteristics of the Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension (ACCOMPLISH) trial.
Bakris G; Hester A; Weber M; Dahlof B; Pitt B; Velasquez E; Staikos-Byrne L; Shi V; Jamerson K;
J Cardiometab Syndr; 2008; 3(4):229-33. PubMed ID: 19040592
[TBL] [Abstract][Full Text] [Related]
10. Combination of amlodipine plus angiotensin receptor blocker or diuretics in high-risk hypertensive patients: a 96-week efficacy and safety study.
Ma L; Wang W; Zhao Y; Zhang Y; Deng Q; Liu M; Sun H; Wang J; Liu L
Am J Cardiovasc Drugs; 2012 Apr; 12(2):137-42. PubMed ID: 22329591
[TBL] [Abstract][Full Text] [Related]
11. [Comparison of benazepril monotherapy to amlodipine plus benazepril in the treatment of patients with mild and moderate hypertension: a multicentre, randomized, double-blind, parallel-controlled study].
Fan CM; Yan LR; Tao YK; Wang L; Li YQ; Gao MM; Wang YN; Li CX; Wang XW; Lu XL; Pang HM; Li YS
Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Jan; 39(1):57-60. PubMed ID: 21418799
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular events during differing hypertension therapies in patients with diabetes.
Weber MA; Bakris GL; Jamerson K; Weir M; Kjeldsen SE; Devereux RB; Velazquez EJ; Dahlöf B; Kelly RY; Hua TA; Hester A; Pitt B;
J Am Coll Cardiol; 2010 Jun; 56(1):77-85. PubMed ID: 20620720
[TBL] [Abstract][Full Text] [Related]
13. Prior Medications and the Cardiovascular Benefits From Combination Angiotensin-Converting Enzyme Inhibition Plus Calcium Channel Blockade Among High-Risk Hypertensive Patients.
Brook RD; Kaciroti N; Bakris G; Dahlöf B; Pitt B; Velazquez E; Weber M; Zappe DH; Hau T; Jamerson KA
J Am Heart Assoc; 2018 Jan; 7(1):. PubMed ID: 29301757
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and duration of benazepril plus amlodipine or hydrochlorothiazide on 24-hour ambulatory systolic blood pressure control.
Jamerson KA; Devereux R; Bakris GL; Dahlöf B; Pitt B; Velazquez EJ; Weir M; Kelly RY; Hua TA; Hester A; Weber MA
Hypertension; 2011 Feb; 57(2):174-9. PubMed ID: 21189401
[TBL] [Abstract][Full Text] [Related]
15. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial.
Julius S; Kjeldsen SE; Weber M; Brunner HR; Ekman S; Hansson L; Hua T; Laragh J; McInnes GT; Mitchell L; Plat F; Schork A; Smith B; Zanchetti A;
Lancet; 2004 Jun; 363(9426):2022-31. PubMed ID: 15207952
[TBL] [Abstract][Full Text] [Related]
16. Predictors of systolic BP <140 mmHg and systolic BP level by randomly assigned treatment group (benazepril plus amlodipine or hydrochlorothiazide) in the ACCOMPLISH Study.
Kjeldsen SE; Jamerson KA; Bakris GL; Pitt B; Dahlöf B; Velazquez EJ; Hua TA; Kelly RY; Zappe D; Hester A; Tuomilehto J; Ostergren J; Ibsen H; Weber M;
Blood Press; 2012 Apr; 21(2):82-7. PubMed ID: 21830844
[TBL] [Abstract][Full Text] [Related]
17. Comparison of benazepril-amlodipine and captopril-thiazide combinations in the management of mild-to-moderate hypertension.
Malacco E; Piazza S; Carretta R; Di Somma S; Mugellini A; Bertocchi F; Palatini P;
Int J Clin Pharmacol Ther; 2002 Jun; 40(6):263-9. PubMed ID: 12078940
[TBL] [Abstract][Full Text] [Related]
18. Magnetic resonance imaging left ventricular mass reduction with fixed-dose angiotensin-converting enzyme inhibitor-based regimens in patients with high-risk hypertension.
Reichek N; Devereux RB; Rocha RA; Hilkert R; Hall D; Purkayastha D; Pitt B
Hypertension; 2009 Oct; 54(4):731-7. PubMed ID: 19687350
[TBL] [Abstract][Full Text] [Related]
19. Pharmacoeconomic evaluation of stroke and myocardial infarction prevention in hypertensive patients: Markov model based on the ACCOMPLISH trial.
Feng A; Lin W; Li L; Zeng M; Lyu J
J Int Med Res; 2023 Dec; 51(12):3000605231214921. PubMed ID: 38114070
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of amlodipine/olmesartan medoxomil ± HCTZ in obese patients uncontrolled on antihypertensive monotherapy.
Hsueh WA; Shojaee A; Maa JF; Neutel JM
Curr Med Res Opin; 2012 Nov; 28(11):1809-18. PubMed ID: 23072496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
